• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    A Vaccine Based on the Receptor-Binding Domain of the Spike Protein Expressed in Glycoengineered Pichia pastoris Targeting SARS-CoV-2 Stimulates Neutralizing and Protective Antibody Responses

    2022-08-17 01:51:04BoLiuYingYinYuxioLiuTintinWngPengSunYngqinOuXinGongXuchenHouJunZhngHonggungRenShiqingLuoQinKeYongmingYoJunjieXuJunWu
    Engineering 2022年6期

    Bo Liu, Ying Yin, Yuxio Liu, Tintin Wng, Peng Sun, Yngqin Ou, Xin Gong,Xuchen Hou, Jun Zhng, Honggung Ren, Shiqing Luo,e, Qin Ke,e, Yongming Yo*,Junjie Xu,*, Jun Wu,*

    a Department of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing 100071, China

    b Medical Innovation Research Division & Fourth Medical Center of the Chinese PLA General Hospital, Beijing 100853, China

    c Department of Neurosurgery, First Medical Center of the Chinese PLA General Hospital, Beijing 100853, China

    d Shenzhen Taihe Biotechnology Co. Ltd., Shenzhen 518001, China

    e Institute of Physical Science and Information Technology, Anhui University, Hefei 230000, China

    Keywords:Coronavirus SARS-CoV-2 Vaccine Yeast Receptor-binding domain (RBD)

    ABSTRACT In 2020 and 2021, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus,caused a global pandemic. Vaccines are expected to reduce the pressure of prevention and control, and have become the most effective strategy to solve the pandemic crisis. SARS-CoV-2 infects the host by binding to the cellular receptor angiotensin converting enzyme 2(ACE2)via the receptor-binding domain(RBD)of the surface spike(S)glycoprotein.In this study,a candidate vaccine based on a RBD recombinant subunit was prepared by means of a novel glycoengineered yeast Pichia pastoris expression system with characteristics of glycosylation modification similar to those of mammalian cells. The candidate vaccine effectively stimulated mice to produce high-titer anti-RBD specific antibody. Furthermore, the specific antibody titer and virus-neutralizing antibody (NAb) titer induced by the vaccine were increased significantly by the combination of the double adjuvants Al(OH)3 and CpG. Our results showed that the virus-NAb lasted for more than six months in mice. To summarize, we have obtained a SARS-CoV-2 vaccine based on the RBD of the S glycoprotein expressed in glycoengineered Pichia pastoris,which stimulates neutralizing and protective antibody responses. A technical route for fucose-free complex-type N-glycosylation modified recombinant subunit vaccine preparation has been established.

    1. Introduction

    The global pandemic caused by the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has resulted in the infection of more than 99 million people and the deaths of 2.13 million people worldwide until 25 January 2021 [1]. SARS-CoV-2 binds to the host angiotensin converting enzyme 2 (ACE2) receptor via the receptor-binding domain (RBD) region of the spike (S) protein[2]. A change in the conformation of the S protein triggers membrane fusion,permitting virus invasion into cells.Studies have shown that RBD-specific antibodies can bind to either the upstream or downstream conformation of the RBD or to structures other than the ACE2 binding site, thereby blocking the binding of the RBD to ACE2 [3]; this makes the RBD an ideal antigen for neo-coronavirus vaccines[4,5].In vaccine design,therefore,inducing the immune system to produce antibodies against the RBD region in the S glycoprotein may be effective in preventing virus infection.

    The RBD contains two glycosylation sites,N331 and N343[6].At present, vaccines directed to the S protein or the RBD protein as antigens are produced by insect cells or mammalian cells [4,5].The production cycles of these two vaccine platforms are relatively long and have a relatively high cost. Yeast is an ideal proteinpreparation platform,as it is characterized by fast growth,low production cost,and rapid production[7].Yeast also has the ability of protein post-translational modifications, such as N-glycosylation[8]. However, N-glycosylation in yeast leads to hypermannosylation, which will cause protein epitope masking and high-level structural changes, thus affecting the immunogenicity and protective effect of the vaccine. Glycosylation engineering has led to the production of glycoengineered Pichia pastoris yeast,which performs glycosylation similar to that of mammalian cells while retaining the advantages of fast growth, low cost, and rapid reaction [9,10]. The H7N9 hemagglutinin glycoprotein vaccine expressed by glycoengineered yeast has been shown to have good immunogenicity and protective effects [11].

    Over the course of transmission, the virus continues to mutate,and these mutations confer various advantages. For example, the D614G mutation of the S glycoprotein increases the infectivity of the virus, and the N493K mutation in the RBD domain enhances the affinity of the RBD with the host ACE2 receptor by adding a pair of salt bridges [12]. The N493K mutation also reduces the binding capacity of the RBD with several monoclonal antibodies(including REGN10933, REGN10987, LY-CoV555, and s309, which are in clinical trials),thus enabling immune escape.An effective and safe vaccine is the most promising means of preventing the spread of the virus. The glycoengineered yeast expression system will be chosen to develop vaccines based on mutants of the virus S glycoproteins, as it is an industrial-scale system that can produce the candidate vaccines.

    In this study,the RBD glycoprotein of SARS-CoV-2 was expressed in glycoengineered yeast,and the administration of the RBD assisted by the aluminum hydroxide(Al(OH)3) and CpG adjuvants induced the production of virus-neutralizing antibody(NAb)in mice.

    Adjuvants are parts of vaccines that are used to enhance the magnitude, breadth, and durability of the immune response. At present, aluminum adjuvants are the most widely used adjuvants.Their wide application benefits from their effectiveness in a variety of vaccines, better safety (with only slight side effects), and lower price. Two types of aluminum adjuvants are commonly used in licensed vaccines: aluminum hydroxide adjuvant (AH) and aluminum phosphate adjuvant (AP) [13]. Although aluminum adjuvants have been used for many years, their immuneenhancement mechanism has not been fully explained. At present, the most recognized immune-enhancement mechanism of aluminum adjuvants is the‘‘depot effect”that involves the slow release of antigens from the site of immunization. Aluminum adjuvants tend to stimulate a T helper cell 2 (Th2) immune response. CpG oligodeoxynucleotides (ODNs) are a new type of vaccine adjuvant. They are ligands for Toll-like receptor 9 (TLR9),and can induce a T helper cell 1 (Th1) immune response. Three major classes of stimulatory CpG ODNs have been identified based on their structural characteristics and their activity on human peripheral blood mononuclear cells (PBMCs)—particularly on B cells and plasmacytoid dendritic cells (pDCs) [14]. CpG1018 is a CpG-B class oligonucleotide adjuvant that is currently being evaluated in clinical trials as a potential vaccine adjuvant for coronavirus disease 2019 (COVID-19) vaccines. The CpG-based hepatitis B virus (HBV) vaccine Heplisav-B, which is an improved HBV vaccine licensed for use in adults(age>18 years),offers a simplified two-dose regimen compared with other HBV vaccines[15].

    2. Material and methods

    2.1. Yeast strain, bacterial strain, plasmids, and materials

    The glycoengineered Pichia pastoris was reconstructed according to a previously reported method [16], which has also been described in our previous work [11]. The bacterial strain was cultured in Luria–Bertani (LB) medium containing 1.5% agar. The Escherichia coli DH5α (TakaRa Biotech, China) used for cloning was cultured at 37°C. Yeast extract, agar, and tryptone were purchased from OXOID (UK); a yeast nitrogen base without amino acids was obtained from Difco (USA); fetal bovine serum (FBS)was obtained from Beijing Qianzhao Xinye Biology Science and Technology Co., Ltd. (China); and T4 DNA ligase, restriction endonuclease, DNA ladder, Q5 DNA polymerase, and a molecular weight protein marker were obtained from New England Biolabs(USA). Anti-SARS-CoV RBD antibody and horseradish peroxidase(HRP)-goat anti-rabbit immunoglobulin G (IgG) antibody were obtained from Sino Biological (China). The DNA extraction kit and yeast genomic DNA kit were purchased from Sigma (USA).

    2.2. Cloning and expression of the SARS-CoV-2 RBD

    The SARS-CoV-2 RBD gene (GenBank accession number MN908947.3) was codon-optimized and synthesized by Tsingke(China). The RBD gene was cloned into the XhoI and NotI sites in the pPICZαA vector(Invitrogen,USA)to yield pPICZαA-RBD,which is driven by the AOX I promoter. The plasmid pPICZαA-RBD linearized with BglII was transformed into glycoengineered yeast by means of electroporation, and the resulting yeast was designated as Glycoeng-yeast/RBD. The Glycoeng-yeast/RBD clones were screened by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot using the anti-SARS-CoV RBD antibody and the HRP goat anti-rabbit IgG antibody(dilution ratio of 1:2500).

    2.3. Yeast fermentation and the RBD purification procedure

    Fermentations in 50 L bioreactors were conducted according to the methods described earlier [17]. In brief, the seed culture contained 200 mL of seed culture in yeast extract–peptone–dextrose(YPD) media. The fermentation culture contained 10 g yeast extract, 20 g peptone, 40 g glycerol, 4×10–3g biotin, 4.47 g Na2HPO4, 8.22 g NaH2PO4, and 13.4 g yeast nitrogen base (YNB)per liter of culture medium. The fermentations were carried out using the following conditions: The pH was controlled to 6.4 with NH4OH and the temperature was set at 25°C. After a 10 min starvation phase, the methanol feed (100% methanol with 12 mL?L–1Pichia trace minerals (PTM1) salts) was initiated.Methanol induction was continued for 45–50 h.

    The fermentation supernatant was recovered by centrifugation at 8000 revolutions per minute(rpm)for 25 min and then collected for RBD purification.The samples were sequentially subjected to a multimodal weak cation exchange (Capto MMC; GE Healthcare,USA), hydrophobic chromatography (Phenyl Sepharose High Performance; GE Healthcare, USA), strong anion exchange (Source 30Q; GE Healthcare, USA), strong cation exchange (Source 30S;GE Healthcare, USA), and size-exclusion chromatography (SEC;Superdex-200; GE Healthcare, USA) to finally obtain high-purity RBD protein.

    2.4. Characterization of SARS-CoV-2 RBD

    The purified recombinant RBD was analyzed using 12% SDSPAGE and treated with peptide-N-asparagine amidase (PNGase) F at 37°C. The purity of the RBD was analyzed by means of SEC–high-performance liquid chromatography (SEC–HPLC) and reverse-phase-high-performance liquid chromatography (RPHPLC). Absorbance values were recorded at 280 nm (Agilent 1260 HPLC).The recombinant RBD was analyzed using C8 RP-HPLC with a gradient of 0–100% mobile phase B over 40 min. Mobile phase A was composed of 0.1% formic acid (FA), and mobile phase B was composed of 95% acetonitrile and 0.1% FA.

    The binding capacity of the RBD produced from yeast cells and that produced from mammalian cells to human ACE2 was measured via enzyme-linked immunosorbent assay (ELISA). The solution of ACE2 was placed in a flat-bottomed 96-well plate at a final concentration of 10 μg?mL-1, coated with buffer(50 mmol?L–1carbonate, pH 9.6), and left at 4°C overnight. The plate was washed four times with a blocking solution of phosphate-buffered saline containing 0.1% Tween-20 (poly(butylene succinate-co-butylene terephthalate) (PBST)). Next, blocking solution in PBST containing 5% skim milk was added to the plate,which was then incubated for 1 h at 37°C. Serially diluted recombinant RBD was added,incubated at 37°C for 1 h,and then washed four times. The anti-SARS-CoV-2 RBD antibody was diluted by 1:2000 and added to the wells. After being incubated at 37°C for 1 h, the plates were washed four times. The goat anti-rabbit IgG horseradish peroxidase (HRP) binding antibody was diluted 1:2000 and added to the wells. After being incubated at 37°C for 1 h, the plates were washed four times and then developed with 3,3′,5,5′-tetramethylbenzidine for 15 min. 2 mol?L–1H2SO4stop solution at 50 μL per well was added to stop the reaction.

    2.5. Glycoform analysis experiment

    The DNA sequencer-assisted–fluorophore-assisted carbohydrate electrophoresis (DSA–FACE) method described previously[15]was used to detect oligosaccharide chains on the RBD.In brief,the glycoprotein was treated by glucosidase, and the sugar chains were marked with the fluorescent marker 8-aminopyrene-1,3,6-trisulfonic acid (APTS). The samples were separated under an ABI 3100 DNA sequencer (USA).

    2.6. Mice and vaccinations

    BALB/c mice were obtained from Beijing Weitong Lihua Laboratory Animal Technology Co.,Ltd.and raised at the Animal Center of the Beijing Institute of Biotechnology.All animal experiments were approved by the Institutional Animal Care and Use Committee of the Beijing Institute of Biotechnology and conducted in accordance with the institutional guidelines of the committee.The experimental animal welfare ethics number is IACUC-DWZX-2020-039.

    Female BALB/c mice aged 6–8 weeks were randomly divided into three groups(n=10)as the first batch of animal experiments:the 10 μg RBD/100 μg aluminum hydroxide(CRODA,Denmark)gel group; the 10 μg RBD/100 μg aluminum hydroxide gel/25 μg CpG group; and the phosphate-buffered saline (PBS) control group.Mice were immunized with 100 μL (intramuscular injection) in their hind leg muscles on days 0, 14, and 28.

    To determine the optimal immune dose of the RBD, 6–8 weekold BALB/c female mice were randomly divided into four groups(n=5) as the second batch of animal experiments: the 10 μg RBD/50 μg aluminum hydroxide gel/25 μg CpG group; the 5 μg RBD/50 μg aluminum hydroxide gel/25 μg CpG group; the 2.5 μg RBD/50 μg aluminum hydroxide gel/25 μg CpG group; and the PBS control group. Mice were immunized with 100 μL (intramuscular injection) in their hind leg muscles on days 0 and 14. To determine the best immunization strategy, we immunized the BALB/c mice at different times (n=5) as the third batch of animal experiments: two immunizations at days 0 and 14, respectively;two immunizations at days 0 and 21,respectively;two immunizations at days 0 and 28, respectively; and three immunizations at days 0, 14, and 28, respectively. The mice were immunized with 100 μL of 10 μg RBD/50 μg aluminum hydroxide gel/25 μg CpG(intramuscular injection) in their hind leg muscles.

    2.7. Histology and immunohistochemistry

    The five animals of each group in the first batch of animal experiments were decapitated four weeks after the last vaccine injection. The organs, including the hearts, lungs, livers, and spleens, were collected and fixed with formaldehyde, embedded in paraffin, and cut into slices. These sections were stained with hematoxylin and eosin,observed with a light microscope,and analyzed for histology.

    2.8. Analysis of RBD-specific serum antibodies

    The five animals of each group in the first batch of animal experiments were bled on days 14,28,42,98,154,and 182(weeks 2,4,6,14,22,and 26).The animals of the second and third batches of animal experiments were bled two weeks after the first and last vaccination. After the blood had clotted for 1–2 h at room temperature, the samples were centrifuged at 5000 rpm at 4°C for 15 min. The upper serum was collected and stored at –20°C.The recombinant RBD was coated onto a flat-bottom 96-well plate at a final concentration of 2 μg?mL-1in coating buffer(50 mmol?L–1carbonate, pH 9.6), and then left at 4°C overnight. The plate was washed four times with PBST. Next, blocking solution in PBST containing 5% skim milk was added to the plate, which was then incubated for 1 h at 37°C. Serially diluted mouse serum was then added. The plate was incubated at 37°C for 1 h, and then washed four times. The goat anti-mouse IgG HRP binding antibody was diluted to 1:4000 and added to the wells. After being incubated at 37°C for 1 h, the plates were washed four times and developed with 3,3′,5,5′-tetramethylbenzidine for 15 min. 2 mol?L–1H2SO4stop solution at 50 μL per well was then added to stop the reaction.The absorbance was detected on a 450 nm microplate reader.

    2.9. SARS-CoV-2 neutralization assay

    A micro-neutralization assay was used to detect the neutralization activities of the immunized mice serum in the biosafety level 3(BSL-3) facility [16]. In brief, serially diluted sera were incubated with 100 50% tissue culture-infectious dose (TCID50) of the SARS-CoV-2 strain (IME-BJ01) at 37°C for 2 h. Thereafter, the virus-serum complexes were transferred to a monolayer of Vero E6 cells cultured in 96-well plates.The inoculated plates were then incubated for 72 h and stained with 0.05%crystal violet for 35 min.Optical density(OD)values were measured at 570 or 630 nm after the addition of the decolorization solution. The neutralization results were calculated using the Reed-Muench method in order to estimate the serum dilution (50% effective concentration(EC50)titer)required to obtain half of the maximum neutralization of the infection. Seropositivity was defined as a titer ≥16. The initial serum dilution (1:16) was set as the confidence limit of the assay.

    Neutralizing activities against the SARS-CoV-2 501Y.V2 and B.1.1.7 pseudoviruses in the immunized mice serum were tested.The EC50was defined as the serum dilution at which the relative light units (RLUs) were reduced by 50% compared with the virus control wells(virus+cells)after the subtraction of the background RLUs in the control groups with cells only.In brief,the pseudovirus was incubated with serial dilutions of the test samples (six dilutions in a three-fold step-wise manner) in duplicate for 1 h at 37°C, together with the virus control and cell control wells in sexaplicate.Freshly trypsinized cells were then added to each well.After 24 h of incubation in a 5%carbon dioxide(CO2)environment at 37°C, the luminescence was measured, as described in section on pseudovirus titration. The EC50values were calculated with nonlinear regression—that is, log (inhibitor) versus response (four parameters)—using GraphPad Prism 8 (GraphPad Software, Inc.,USA).

    3. Results

    3.1. Expression of SARS-CoV-2 RBD protein in glycoengineered Pichia pastoris

    The RBD of the S protein was prepared using the glycoengineered Pichia pastoris expression system, which has mammalian N-glycosylation modification capacity[12].The RBD gene sequence of SARS-CoV-2 encodes a glycoprotein of 223 amino acids(residues 319–541 of the S protein) with a theoretical molecular mass of 25 kilodalton (kDa) and two N-glycosylation sites (N331 and N343). A schematic of the S protein containing the RBD gene and the expression vector for the RBD gene are shown in Figs. 1(a)and (b), respectively. The RBD gene was cloned between the XhoI and NotI sites of the pPICZαA vector to generate pPICZαARBD (SARS-CoV-2) (Fig. 1(b)). The linearized pPICZαA-RBD was transformed into glycoengineered yeast, and the resultant yeast strain was designated as Glycoeng-yeast/RBD. The results from Western blot testing revealed that all of the examined Glycoengyeast/RBD clones had approximately 30 kDa bands (Fig. 1(c)). The observed band from the SDS-PAGE analysis was heterogeneous,but the observed molecular weight (30 kDa) was higher than the theoretical molecular mass of 25 kDa, which may be because of the glycosylation of RBD.

    3.2.Efficient purification of RBD from glycoengineered Pichia pastoris

    We established a 4 L scale yeast fermentation process,with the whole fermentation cycle lasting for five days (Fig. 2(a)). Because RBD carries an α-factor secretion signal peptide (Fig. 1(b)), the expressed RBD was secreted into the culture supernatant. SDSPAGE analysis of the supernatant from yeast induced at different time points showed that the expression level of the RBD was high after 48 h of induction(Fig.2(b)).The RBD secreted into the supernatant was obtained by means of a cation exchange column,hydrophobic chromatography,anion chromatography,cation chromatography, and gel filtration chromatography. High-purity RBD protein was obtained with a yield of 50 mg?L–1.SDS-PAGE analysis confirmed that the purified RBD protein ran as a single band(Fig.2(c)). The RBD protein showed single, sharp SEC–HPLC (TSK gel G2000SWXL, 5 μm, φ 7.8 mm×300 mm) and RP–HPLC (Agilent ZORBAX 300SB-C8,5 μm,φ 4.6 mm×250 mm)profiles,indicating high purity and integrity (Fig. 2(d)). The binding capacity of the RBD produced from yeast cells and mammalian cells to human ACE2 was measured by ELISA. The absorbance was detected on a microplate reader of 450 nm. The results indicated no significant difference between the binding capacity of the RBD produced from yeast cells and that produced from mammalian cells to human ACE2 (P=0.5784) (Fig. 2(e)).

    3.3. Purified RBD shows complex glycosylated modifications

    The apparent molecular mass of the purified RBD protein(approximately 30 kDa)was about 25%greater than the theoretical molecular mass (approximately 25 kDa). The RBD protein treated with PNGase F was consistent with theoretical mass of 25 kDa (Fig. 3(a)), suggesting that the RBD had undergone N-glycosylation modification. The RBD expressed by glycoengineered yeast had a terminally biantennary galactosylated glycan,as analyzed by DSA–FACE (Fig. 3(b)). DSA–FACE was used to characterize the RBD N-glycans by using bovine ribonuclease B as a marker,and five kinds of glycans(Man5GlcNAc2to Man9GlcNAc2,or M5–M9) were identified (Fig. 3(b-I)) [18]. The glycans of the RBD expressed in yeast were incubated with β1-4-galactosidase, β-N-acetylglucosaminidase, and α1-2,3 mannosidase,respectively,or with a mixture of β1-4-galactosidase and β-N-acetylglucosaminidase. The β1-4-galactosidase removed the terminal galactoses on the N-glycan from Gal2GlcNAc2Man3-GlcNAc2, resulting in the generation of GlcNAc2Man3GlcNAc2(Fig. 3(b-IV)). The β-N-acetylglucosaminidase further cut the N-acetylglucosamine from the N-glycans to generate Man3GlcNAc2(Fig. 3(b-V). The α1-2,3 mannosidase was used to generate Man2GlcNAc2from Man5GlcNAc2(Fig. 3(b-VI)). Over all, the yeast-expressed RBD was modified at the afucosylated mannosetype and complex glycans characterized as Man5GlcNAc2and Gal2-GlcNAc2Man3GlcNAc2(Fig. 3(b-II)). In comparison, previous work on HEK293-derived and Chinese hamsters ovary cells-derived RBD has shown that they mainly possess fucosylated diantennary and triantennary complex-type N-glycans and have a small amount of high mannose N-glycans (Man5, Man6) with or without phosphorylation [19].

    Fig.1. Characterization and expression of the RBD protein of SARS-CoV-2.(a)Schematic of the SARS-CoV-2 S protein sequence,showing the N-terminal domain(NTD),RBD,heptad repeats 1 and 2 (HR1 and HR2), transmembrane domain (TM), subdomains 1 and 2 (SD1 and SD2), fusion peptide (FP), and transmembrane region (TM). Nglycosylation sites are marked with the residue numbers(331 and 343).(b)Map of the pPICZαA-RBD plasmid.(c)SDS-PAGE and Western blot analysis of various Glycoengyeast/RBD clones, shown in lanes 1, 2, 3, and 4. M: marker; CYC1: cytochrome C1; EM7: synthetic prokaryotic promoter that drives constitutive expression of the Zeocin resistance gene in Escherichia coli; TEF1: translation elongation factor 1; AOX1: aldehyde oxidase 1; BleoR: bleomyicin-R.

    Fig.2. Fermentation of yeast35/RBD and the RBD purification procedure.(a)The complete fermentation process of the RBD protein,showing the stirring speed(STIRR;black),dissolved oxygen(pO2;red),variations of temperature(TEMP;blue),base filling amount(BASE;dark green),pH(light green),and acid filling amount(ACID;purple).(b)SDSPAGE analysis of RBD expression at different culture times. (c) SDS-PAGE of the RBD during the purification process. (d) SEC–HPLC and RP–HPLC of the purified RBD.(e) Binding capacity to human ACE2 of RBD produced from yeast cells and RBD produced from mammalian cells. Phenyl HP: phenyl sepharose high performance;G25 fine:Sephadex G25 coarse; Superdex-200: Superdex-200 prep grade; OD450: optical density at 450 nm; AU: absorbance unit.

    Fig. 3. Characterization of the RBD. (a) SDS-PAGE results of RBD digested with PNGase F.(b)N-glycans analysis of the RBD protein:(I)Reference glycans of bovine RNase B (Man5GlcNAc2–Man9GlcNAc2); (II) N-glycans of RBD protein; (III) glycans of RBD digested with β-N-acetylglucosaminidase;(IV)glycans of RBD digested with β1-4-galactosidase; (V) glycans of RBD digested with β-N-acetylglucosaminidase and β1-4-galactosidase; (VI) glycans of RBD digested with α1-2,3 mannosidase.PNGF: peptide-N-glycosidase F; RFU: relative fluorescence unit.

    3.4. Identification of antibodies against RBD

    To develop vaccines using the RBD, we selected aluminum hydroxide as the adjuvant for its safety and effectiveness. To prepare the vaccine, aluminum hydroxide was added to the RBD,resulting in precipitation of the candidate vaccine with aluminum gel.To evaluate the potential of the RBD as a vaccine,the RBD was given to BALB/c mice with CpG (CpG2006) [13,20] and aluminum hydroxide as double adjuvants. PBS was given as the control. At 14 days after the last immunization, serum samples were collected.

    The RBD immunogen with the combination of CpG and aluminum hydroxide as the adjuvants markedly increased the immunogenicity of the antibody titer (Fig. 4(a)). At 14 days after the first immunization, the specific antibody titers of the RBD+Al(OH)3+CpG group and the RBD+Al(OH)3group were 7.4×104and 66.0, respectively (P<0.0001). At 14 days after the second immunization,the antibody titer of the RBD+Al(OH)3+CpG group was 6.8×106and that of the RBD+Al(OH)3group was 7.9×103. The RBD+Al(OH)3+CpG group induced a significantly higher antigen-specific IgG compared with the RBD+Al(OH)3group(P<0.0001). Because of the low antibody titer in the RBD+Al(OH)3group, a third immunization was performed. Two weeks later, the antibody titer of the RBD+Al(OH)3group was 3.4×105,but that of the RBD+Al(OH)3+CpG group(i.e.,four weeks after the second immunization) without the third immunization was approximately 4.5×106(P<0.0001). These results indicated that the RBD with both CpG and aluminum hydroxide was superior to the RBD with the aluminum hydroxide adjuvant as an immunogen.

    We next tested sera from the groups for neutralizing activities against live SARS-CoV-2 virus (IME-BJ01) (Fig. 4(b)). At 14 days after the first immunization, the titers of NAb in the RBD+Al(OH)3+CpG group and the RBD+Al(OH)3group were below 1:16, which was basically the same as that in the negative control group. At 14 days after the second immunization, the NAb titer of the RBD+Al(OH)3group was still below 1:16, but that of the RBD+Al(OH)3+CpG group was 1:1000 (ranging from 430 to 2800). The RBD+Al(OH)3+CpG group elicited higher titers of NAb compared with the RBD+Al(OH)3group(P<0.05).At 14 days after the third immunization, the NAb titer was 1:105 (ranging from 33 to 210) in the RBD+Al(OH)3group; the NAb titer in the RBD+Al(OH)3+CpG group without the third immunization (four weeks after the second immunization) was 1:1259 (ranging from 310 to 1900) (P<0.05).

    To determine the optimal immunity dose of RBD,we performed the experiment with different doses of the RBD antigen.At 14 days after the first immunization, the antibody titers of the 10 μg RBD group and the 5 μg RBD group were 7.9×104and 5.0×104(P=0.1268) (Fig. 4(c)). The antibody titer of the 2.5 μg RBD group was 5.0×104, which was not significantly different from that of the 10 μg RBD group (P=0.1268). At 14 days after the second immunization, the antibody titers of the 10 μg RBD group and the 5 μg RBD group were 3.2×106and 2.5×106, respectively(P=0.3739). The antibody titer of the 2.5 μg RBD group was 1.0×106, and less antigen-specific IgG was induced compared with the 10 μg RBD group(P<0.05).These results indicated no significant difference in the antibody titer induced by 10 μg or 5 μg of RBD antigen immunization to BALB/c mice with 50 μg Al(OH)3and 25 μg CpG per dose; however, the immunity effect using 2.5 μg RBD was poor.

    Fig.4. Immunity effects of vaccines with different adjuvant components on BALB/c mice.(a)Antibody titers after three immunizations with vaccines with different adjuvant components; no third immunization was performed in the RBD+Al(OH)3+CpG group. (b) Antibody neutralizing activity of vaccines with different adjuvant components after three immunizations;no third immunization was performed in the RBD+Al(OH)3+CpG group.(c)Antibody titers of 100 μL vaccine preparations mixed with different doses of RBD (10.0, 5.0, and 2.5 μg), 50 μg of Al(OH)3 adjuvant and 25 μg of CpG for 14 days and 28 days after the first immunization. (d) Antibody titers at 14 days after immunization with the RBD vaccine with different immunization strategies(5 μg RBD mixed with 50 μg Al(OH)3 adjuvant and 25 μg CpG mixed in 100 μL).ns:no significant difference; NS: normal saline. P-values were analyzed with t tests; ns: p > 0.05, **: p < 0.01, ***: p < 0.001, ****: p < 0.0001.

    To determine the best immunization strategy, we immunized BALB/c mice at different time: two immunizations at days 0 and 14; two immunizations at days 0 and 21; two immunizations at days 0 and 28; and three immunizations at days 0, 14, and 28. At 14 days after the first immunization, no significant difference was found in the antibody titer (Fig. 4(d)). At day 14 after the second immunization, the antibody titers were 4.0×106in the‘‘0,14 d”group and 3.2×106in the‘‘0,21 d”group.The titers were 5.0×106in the ‘‘0, 14, 28 d” group at 14 days after the third immunization and 2.0×106in the‘‘0,28 d”group at 14 days after the second immunization. The ‘‘0, 14, 28 d” group induced significantly more antigen-specific IgG compared with the ‘‘0,28 d”group.No significant difference was noted between the other groups.These results indicate that the‘‘0,14 d,”‘‘0,21 d,”or‘‘0,14,28 d” schedules could be potential immunization strategies.

    3.5. Safety evaluation

    To evaluate the toxicity of the RBD candidate vaccine,histopathological changes of the main organs including the liver,lung, and heart tissues were examined by light microscopy. The results revealed no obvious differences between the experimental and control groups (Fig. 5).

    3.6. Characterization of the persistence of RBD antibody response

    To determine the persistence of the antibody titer,blood samples were collected from the tails of mice at weeks 2,4,6,14,22,and 26 after immunization. The antibody titer of the RBD+Al(OH)3+CpG group was 6.3×106at 14 days and 3.2×106at 12 weeks after the second immunization (Fig. 6(a)) (P=0.0604).The antibody titer was 6.3×105at 22 weeks after immunization and 6.3×105after 26 weeks. The antibody titer of the RBD+Al(OH)3group was 3.2×105at two weeks after the third immunization and 6.3×105at 14 weeks after the immunization(P=0.1823).The antibody titer was 1.6×105at 22 weeks after the immunization,and there was no significant difference with the antibody titer 2 weeks after the third immunization (P=0.1878). At 26 weeks after immunization,the antibody titer was 2.5×104.

    Fig.5. Possible histopathological changes to organs including liver,lung,and heart tissues(stained by hematoxylin and eosin)were observed by means of light microscopy.

    To determine the persistence of the NAb titer, blood was collected at weeks 2, 4, 6, 14, 22, and 26 after the last immunization.The NAb titer of the RBD+Al(OH)3+CpG group was 1:1000(ranging from 430 to 2800)at four weeks after immunization and 1:501(ranging from 250 to 1500) at 26 weeks after immunization(P=0.2218) (Fig. 6(b)). The antibody titer of the RBD+Al(OH)3group was 1:105 (ranging from 33 to 210) at two weeks after the third immunization and 1:63 (ranging from 28 to 170) after 26 weeks (P=0.5545).

    At 14 days after the third immunization, the NAb titer of the RBD+Al(OH)3group against 501Y.V2 was 1:182, and that of the RBD+Al(OH)3+CpG group was 1:347. At 14 days after the third immunization, the NAb titer of the RBD+Al(OH)3group against B.1.1.7 was 1:832, and that of the RBD+Al(OH)3+CpG group was 1:1047. Thus, our data show that the vaccination determined cross-neutralization against B.1.1.7 and 501Y.V2 (Fig. 6(c)).

    4. Discussion

    Similar to the S proteins of other viruses,the S protein of SARSCoV-2 is coated with carbohydrate chains,which potentially mask epitopes to block the host’s immune response.The S protein monomer has 22 N-glycosylation sites[21],with two glycosylation sites,N331 and N343, in the RBD region. Correct glycosylation of antigens is critical for immunogenicity. Many vaccine technologies based on the S protein currently use mammalian cells or insect cells as the expression system in order to ensure the correct glycosylation modification. Yeast, a lower eukaryote, has the ability of hyper-mannosylation. Studies have shown that hypermannosylation modifications may mask the epitope of antigens[22]. The H7N9 influenza virus hemagglutinin (HA) subunit particle vaccine prepared by means of glycosylation-modified humanized yeast, which has mammalian N-glycosylation ability,has been shown to have good immunogenicity and protected mice from the H7N9 virus [11]. In this study, we used glycoengineered Pichia pastoris to express SARS-CoV-2 RBD. DSA–FACE analysis showed that the N-glycosyl groups in the RBD were a fucose-free complex glycosyl group and a low-mannose glycosyl group,which ensured that the RBD epitope could not be masked.

    To examine the safety of the candidate RBD vaccine, we examined the potential toxicity of the RBD vaccine in mice. No adverse effects were observed,such as body weight and behavioral changes(data not shown). There were no significant pathological changes in the liver, lung, heart, and other organs on microscopic examination.

    Fig. 6. Detection of RBD antibody persistence at 6 months after immunization.(a) Antibody titer persistence at 26 weeks after immunization with different adjuvant components. (b) Antibody neutralizing activity persistence at 26 weeks after immunization with different adjuvant components. (c) Neutralizing activities against the SARS-CoV-2 501Y.V2 and B.1.1.7 pseudoviruses. ED50:median effective dose. P-values were analyzed with t tests; ns: p > 0.05, ***: p < 0.001.

    In our study, we found that Al(OH)3combined with CpG had a significant adjuvant effect. In mice, Al(OH)3combined with CpG induced a strong humoral and cellular immune response against the RBD. During the 26-week follow-up, the titer of virus-NAb did not significantly decrease. These results provide immunogenicity research data for a vaccine using RBD expressed by glycoengineered yeast as the immunogen.Importantly,the glycoengineered yeast production platform can quickly respond to virus mutations with an expandable production scale.Thus,the preparation of candidate vaccines can be expected to be completed with a stable production process within a few weeks. The candidate RBD vaccine presented here has the potential to contribute significantly to the control of the COVID-19 pandemic.If the SARS-CoV-2 subunit vaccine with the CpG and Al(OH)3adjuvants proves to be successful,rapid production of viral glycoproteins based on glycoengineered yeast will become an important new technology for rapid response to any emerging viral threat.

    Acknowledgments

    This work was supported by the National Key Research and Development Program of China (2020YFC0841400-008), the NationalScienceandTechnologyMajorProjects(2018ZX09711003-013-002), and the National Natural Science Foundation of China (81673339 and 81773619).

    Compliance with ethics guidelines

    Bo Liu, Ying Yin, Yuxiao Liu, Tiantian Wang, Peng Sun, Yangqin Ou, Xin Gong, Xuchen Hou, Jun Zhang, Hongguang Ren, Shiqiang Luo, Qian Ke, Yongming Yao, Junjie Xu, and Jun Wu declare that they have no conflict of interest or financial conflicts to disclose.

    黄片小视频在线播放| 欧美另类亚洲清纯唯美| 真实男女啪啪啪动态图| 亚洲专区国产一区二区| 日韩 欧美 亚洲 中文字幕| or卡值多少钱| 国产精品美女特级片免费视频播放器 | 色综合欧美亚洲国产小说| 可以在线观看毛片的网站| 亚洲国产高清在线一区二区三| 成人三级黄色视频| 搡老妇女老女人老熟妇| 91麻豆av在线| 国语自产精品视频在线第100页| 亚洲国产精品999在线| 国产一区二区三区在线臀色熟女| 国产日本99.免费观看| 可以在线观看毛片的网站| 999久久久精品免费观看国产| 婷婷六月久久综合丁香| 国产精品久久久久久人妻精品电影| 亚洲一区高清亚洲精品| 免费看光身美女| 国产男靠女视频免费网站| 国产精品九九99| 香蕉国产在线看| 国产 一区 欧美 日韩| 色老头精品视频在线观看| 日韩成人在线观看一区二区三区| 亚洲七黄色美女视频| 美女高潮的动态| 国产伦精品一区二区三区四那| 色哟哟哟哟哟哟| 欧美黄色片欧美黄色片| 精品一区二区三区视频在线 | 国产精品亚洲一级av第二区| 亚洲av美国av| 一级作爱视频免费观看| 麻豆一二三区av精品| 一进一出抽搐gif免费好疼| 亚洲精品色激情综合| 性色avwww在线观看| 国产精品永久免费网站| 久久精品91蜜桃| 香蕉av资源在线| 日本 欧美在线| 成人亚洲精品av一区二区| 亚洲va日本ⅴa欧美va伊人久久| 色在线成人网| 最近最新免费中文字幕在线| 午夜久久久久精精品| 变态另类成人亚洲欧美熟女| 国产精品,欧美在线| 欧美成人一区二区免费高清观看 | 一二三四社区在线视频社区8| 一本久久中文字幕| 国产激情欧美一区二区| 精品人妻1区二区| 露出奶头的视频| 非洲黑人性xxxx精品又粗又长| 一级毛片精品| 最好的美女福利视频网| 偷拍熟女少妇极品色| 久久久久性生活片| 少妇熟女aⅴ在线视频| 亚洲国产精品999在线| 18禁美女被吸乳视频| 少妇的丰满在线观看| 老司机深夜福利视频在线观看| 午夜福利18| 国产精品av久久久久免费| 国内精品久久久久久久电影| 亚洲国产日韩欧美精品在线观看 | 偷拍熟女少妇极品色| 久久久国产成人精品二区| 欧美乱色亚洲激情| 国产伦精品一区二区三区视频9 | 夜夜夜夜夜久久久久| 欧美日本视频| 少妇丰满av| 男女视频在线观看网站免费| 日本三级黄在线观看| 欧美日韩精品网址| www.999成人在线观看| 亚洲欧美日韩高清专用| 91在线观看av| 少妇人妻一区二区三区视频| 久久精品91无色码中文字幕| 天堂网av新在线| 黄色 视频免费看| 19禁男女啪啪无遮挡网站| 国产精品美女特级片免费视频播放器 | 国产精品久久久久久精品电影| 欧美xxxx黑人xx丫x性爽| 久久精品国产99精品国产亚洲性色| 小蜜桃在线观看免费完整版高清| 亚洲美女黄片视频| 男女视频在线观看网站免费| 99热精品在线国产| 国产乱人视频| 欧美在线一区亚洲| 久久久精品大字幕| 日本与韩国留学比较| 国产一区二区激情短视频| 中文字幕熟女人妻在线| 精品电影一区二区在线| 欧美在线黄色| 99在线人妻在线中文字幕| 久久精品91无色码中文字幕| bbb黄色大片| 成年女人毛片免费观看观看9| 成人欧美大片| 曰老女人黄片| 日本五十路高清| 久久亚洲精品不卡| 欧美性猛交黑人性爽| 亚洲欧美一区二区三区黑人| 成年人黄色毛片网站| 国产成人欧美在线观看| 精品国产乱子伦一区二区三区| 不卡av一区二区三区| 日本免费一区二区三区高清不卡| 美女午夜性视频免费| 日韩三级视频一区二区三区| 一个人观看的视频www高清免费观看 | 日本 欧美在线| 色综合欧美亚洲国产小说| 精品福利观看| 国产午夜精品久久久久久| 久久这里只有精品19| 亚洲无线观看免费| 丰满人妻一区二区三区视频av | 首页视频小说图片口味搜索| 黄色成人免费大全| 久久精品综合一区二区三区| 亚洲avbb在线观看| 12—13女人毛片做爰片一| 丰满人妻一区二区三区视频av | 国产成人av激情在线播放| 国产激情偷乱视频一区二区| 婷婷亚洲欧美| 人人妻,人人澡人人爽秒播| 国产精品九九99| 青草久久国产| 午夜成年电影在线免费观看| 国产av麻豆久久久久久久| 无限看片的www在线观看| 不卡一级毛片| 国产高清激情床上av| 露出奶头的视频| 禁无遮挡网站| 欧美极品一区二区三区四区| 精品久久久久久久人妻蜜臀av| 国产精品一区二区精品视频观看| 美女免费视频网站| 久久久久久久午夜电影| 香蕉国产在线看| svipshipincom国产片| 国产亚洲精品一区二区www| av中文乱码字幕在线| 亚洲中文av在线| 亚洲成人久久爱视频| 午夜精品一区二区三区免费看| 精品不卡国产一区二区三区| 日韩成人在线观看一区二区三区| 叶爱在线成人免费视频播放| xxxwww97欧美| 香蕉久久夜色| 最好的美女福利视频网| 香蕉丝袜av| 成熟少妇高潮喷水视频| 三级男女做爰猛烈吃奶摸视频| 免费av毛片视频| 欧美乱妇无乱码| 国产成人av激情在线播放| 国产午夜福利久久久久久| 亚洲精品色激情综合| 这个男人来自地球电影免费观看| e午夜精品久久久久久久| 人人妻人人看人人澡| 成人av一区二区三区在线看| 草草在线视频免费看| 舔av片在线| 精品熟女少妇八av免费久了| 亚洲av成人精品一区久久| 亚洲色图av天堂| 国产一区在线观看成人免费| 欧美性猛交╳xxx乱大交人| 久久性视频一级片| 岛国在线免费视频观看| 成年免费大片在线观看| 色综合婷婷激情| 伊人久久大香线蕉亚洲五| 长腿黑丝高跟| 久9热在线精品视频| 免费一级毛片在线播放高清视频| 18禁观看日本| 岛国视频午夜一区免费看| 真人一进一出gif抽搐免费| 成人一区二区视频在线观看| 日韩欧美 国产精品| 麻豆国产97在线/欧美| 久久久色成人| 少妇的逼水好多| 日本免费一区二区三区高清不卡| 久久久国产精品麻豆| 桃色一区二区三区在线观看| 国产亚洲精品一区二区www| 女同久久另类99精品国产91| 欧美黄色片欧美黄色片| 一进一出抽搐动态| 99久久精品一区二区三区| 免费av不卡在线播放| 国产精品久久久久久精品电影| 亚洲国产欧美一区二区综合| 日本三级黄在线观看| 熟女电影av网| 久久久久久大精品| 久久精品人妻少妇| 长腿黑丝高跟| 亚洲人成伊人成综合网2020| 亚洲av成人一区二区三| 亚洲真实伦在线观看| 精品久久久久久久毛片微露脸| 在线免费观看不下载黄p国产 | 色尼玛亚洲综合影院| 免费无遮挡裸体视频| 香蕉av资源在线| 欧美日韩一级在线毛片| 国产成人精品久久二区二区免费| 99久久久亚洲精品蜜臀av| 琪琪午夜伦伦电影理论片6080| 在线免费观看不下载黄p国产 | 国产高清激情床上av| 日韩高清综合在线| 日本三级黄在线观看| 日本成人三级电影网站| 精品国产美女av久久久久小说| 俺也久久电影网| 免费在线观看日本一区| 国产亚洲av高清不卡| 天堂√8在线中文| 99久久精品国产亚洲精品| 成人高潮视频无遮挡免费网站| 一级a爱片免费观看的视频| 成人午夜高清在线视频| 久久久久久久久免费视频了| 欧美日本视频| 久久久久亚洲av毛片大全| 在线观看美女被高潮喷水网站 | 亚洲精品一卡2卡三卡4卡5卡| 巨乳人妻的诱惑在线观看| 一夜夜www| 蜜桃久久精品国产亚洲av| 欧美日韩综合久久久久久 | 国产黄a三级三级三级人| 欧美日韩福利视频一区二区| 色综合婷婷激情| 日韩欧美精品v在线| 国产精品久久久久久人妻精品电影| 最新美女视频免费是黄的| 悠悠久久av| 亚洲狠狠婷婷综合久久图片| 欧美黄色淫秽网站| 天天一区二区日本电影三级| 国产精品,欧美在线| 99久久国产精品久久久| 老司机深夜福利视频在线观看| 久久精品夜夜夜夜夜久久蜜豆| 国产成人一区二区三区免费视频网站| 老汉色∧v一级毛片| 老鸭窝网址在线观看| 欧美高清成人免费视频www| 国产私拍福利视频在线观看| www.精华液| 午夜免费成人在线视频| 热99re8久久精品国产| 亚洲中文字幕日韩| 亚洲欧美日韩卡通动漫| 亚洲va日本ⅴa欧美va伊人久久| 国产亚洲欧美在线一区二区| 国内精品久久久久精免费| 久久亚洲精品不卡| 色av中文字幕| 国产精品久久久av美女十八| 国产97色在线日韩免费| 此物有八面人人有两片| 在线观看日韩欧美| 每晚都被弄得嗷嗷叫到高潮| 国产精华一区二区三区| 亚洲成av人片在线播放无| 一a级毛片在线观看| 这个男人来自地球电影免费观看| 国产成人精品久久二区二区免费| av国产免费在线观看| 欧美xxxx黑人xx丫x性爽| 中文字幕高清在线视频| 日本 av在线| 无人区码免费观看不卡| 小说图片视频综合网站| 天天添夜夜摸| 一本精品99久久精品77| 精品人妻1区二区| 成人无遮挡网站| 黑人欧美特级aaaaaa片| av黄色大香蕉| 国产毛片a区久久久久| www.999成人在线观看| 久久精品国产99精品国产亚洲性色| 亚洲国产高清在线一区二区三| 国产精品自产拍在线观看55亚洲| 国产激情久久老熟女| 1000部很黄的大片| 精品国产乱码久久久久久男人| 久久这里只有精品19| 亚洲欧美日韩东京热| 亚洲激情在线av| 亚洲国产色片| 欧美精品啪啪一区二区三区| 亚洲,欧美精品.| e午夜精品久久久久久久| 夜夜看夜夜爽夜夜摸| 精品免费久久久久久久清纯| 看免费av毛片| 一区福利在线观看| 99在线视频只有这里精品首页| 国产午夜精品论理片| 久久精品国产亚洲av香蕉五月| 亚洲国产色片| 国产精品乱码一区二三区的特点| 宅男免费午夜| 精品一区二区三区四区五区乱码| 国产精品98久久久久久宅男小说| 99在线人妻在线中文字幕| 欧美成人免费av一区二区三区| 亚洲国产高清在线一区二区三| 国产精品自产拍在线观看55亚洲| 欧美国产日韩亚洲一区| 亚洲 欧美 日韩 在线 免费| 亚洲av电影在线进入| 国产成人啪精品午夜网站| 国产爱豆传媒在线观看| 日本 欧美在线| 欧美日韩国产亚洲二区| 波多野结衣高清作品| 欧美成人免费av一区二区三区| 一进一出抽搐gif免费好疼| 99久久无色码亚洲精品果冻| 亚洲国产日韩欧美精品在线观看 | 曰老女人黄片| 精品免费久久久久久久清纯| 国产伦在线观看视频一区| 精品久久久久久久毛片微露脸| 国产1区2区3区精品| 亚洲精品粉嫩美女一区| 国产激情偷乱视频一区二区| 一个人免费在线观看的高清视频| 好看av亚洲va欧美ⅴa在| 亚洲性夜色夜夜综合| netflix在线观看网站| 色综合站精品国产| 在线国产一区二区在线| 色综合站精品国产| 免费av毛片视频| 黄色丝袜av网址大全| 国产精品久久久人人做人人爽| 国产精品永久免费网站| 精品乱码久久久久久99久播| 欧美一级a爱片免费观看看| 深夜精品福利| 国产欧美日韩精品一区二区| 九九热线精品视视频播放| 男女那种视频在线观看| 日韩 欧美 亚洲 中文字幕| 国产精品久久视频播放| 中国美女看黄片| 日本一本二区三区精品| 精品久久久久久,| av女优亚洲男人天堂 | 91麻豆精品激情在线观看国产| 狂野欧美激情性xxxx| 此物有八面人人有两片| 午夜精品久久久久久毛片777| 成人特级黄色片久久久久久久| 99国产综合亚洲精品| 成人一区二区视频在线观看| 久久99热这里只有精品18| 国产美女午夜福利| 久久国产精品影院| 露出奶头的视频| 国产 一区 欧美 日韩| 欧美av亚洲av综合av国产av| 久9热在线精品视频| 老熟妇乱子伦视频在线观看| 亚洲国产欧美人成| 午夜成年电影在线免费观看| 亚洲精品一区av在线观看| 欧美成狂野欧美在线观看| 又黄又爽又免费观看的视频| a级毛片a级免费在线| 最近最新中文字幕大全电影3| 美女免费视频网站| 精品无人区乱码1区二区| 国产一级毛片七仙女欲春2| 91久久精品国产一区二区成人 | 国产精品永久免费网站| 91av网一区二区| 老司机午夜十八禁免费视频| 精品国产超薄肉色丝袜足j| 亚洲av熟女| 精品国内亚洲2022精品成人| 欧美一区二区国产精品久久精品| 国产精品亚洲美女久久久| 日日干狠狠操夜夜爽| 激情在线观看视频在线高清| 男插女下体视频免费在线播放| av在线蜜桃| 女警被强在线播放| 日韩成人在线观看一区二区三区| 亚洲精品乱码久久久v下载方式 | 一本一本综合久久| 波多野结衣高清无吗| 首页视频小说图片口味搜索| 国产精品av视频在线免费观看| 久久伊人香网站| 国产欧美日韩一区二区三| 男女那种视频在线观看| 欧美性猛交黑人性爽| 欧美乱色亚洲激情| 色精品久久人妻99蜜桃| 亚洲精品在线美女| 国内精品久久久久久久电影| 亚洲国产看品久久| 国产在线精品亚洲第一网站| 亚洲精品国产精品久久久不卡| 亚洲午夜理论影院| 免费人成视频x8x8入口观看| 亚洲精品在线美女| x7x7x7水蜜桃| 99久久精品一区二区三区| 国产一区二区在线av高清观看| 美女被艹到高潮喷水动态| 听说在线观看完整版免费高清| 天天一区二区日本电影三级| 性色avwww在线观看| 成人av一区二区三区在线看| 亚洲一区高清亚洲精品| 99久久精品热视频| 可以在线观看毛片的网站| 俄罗斯特黄特色一大片| 亚洲精品一卡2卡三卡4卡5卡| 久久九九热精品免费| 伊人久久大香线蕉亚洲五| 又爽又黄无遮挡网站| 久久这里只有精品中国| 两个人看的免费小视频| 成人特级av手机在线观看| 亚洲专区字幕在线| www.www免费av| 亚洲成人久久性| 97超级碰碰碰精品色视频在线观看| 亚洲自拍偷在线| 在线免费观看不下载黄p国产 | 国产91精品成人一区二区三区| 欧美日韩福利视频一区二区| 欧美极品一区二区三区四区| 在线国产一区二区在线| 琪琪午夜伦伦电影理论片6080| 久久国产精品人妻蜜桃| 18禁黄网站禁片免费观看直播| 免费看日本二区| 久久国产乱子伦精品免费另类| 日韩有码中文字幕| 欧美三级亚洲精品| 久久精品91无色码中文字幕| 国产视频一区二区在线看| 精品久久久久久久末码| 老司机深夜福利视频在线观看| 亚洲狠狠婷婷综合久久图片| 脱女人内裤的视频| 日韩欧美三级三区| 一本精品99久久精品77| 国产免费av片在线观看野外av| 老司机福利观看| 91av网一区二区| 成人鲁丝片一二三区免费| av中文乱码字幕在线| 97超级碰碰碰精品色视频在线观看| 国产三级中文精品| 在线免费观看不下载黄p国产 | 99re在线观看精品视频| 又爽又黄无遮挡网站| 亚洲欧美日韩无卡精品| 成人鲁丝片一二三区免费| 2021天堂中文幕一二区在线观| 精品一区二区三区四区五区乱码| 此物有八面人人有两片| 国产成人一区二区三区免费视频网站| 国产乱人视频| 国产美女午夜福利| av天堂在线播放| 国产97色在线日韩免费| 男女午夜视频在线观看| 国产成人欧美在线观看| 精品乱码久久久久久99久播| 在线观看舔阴道视频| 久久精品91无色码中文字幕| 日韩精品青青久久久久久| 国产精品久久电影中文字幕| 天堂√8在线中文| 99国产精品一区二区三区| 免费观看的影片在线观看| 女人高潮潮喷娇喘18禁视频| 日韩欧美国产在线观看| 亚洲性夜色夜夜综合| 在线a可以看的网站| 国产成人一区二区三区免费视频网站| 久久欧美精品欧美久久欧美| 亚洲成人久久爱视频| 亚洲在线观看片| 午夜福利在线观看免费完整高清在 | 18禁国产床啪视频网站| 欧美一级毛片孕妇| 久久欧美精品欧美久久欧美| 欧美日韩福利视频一区二区| 999久久久国产精品视频| 久久精品国产99精品国产亚洲性色| 欧美又色又爽又黄视频| 国产成人一区二区三区免费视频网站| 好男人电影高清在线观看| 国内精品久久久久久久电影| 精品久久久久久,| 夜夜夜夜夜久久久久| 亚洲欧美日韩无卡精品| 成人三级做爰电影| 国产高清激情床上av| 国产人伦9x9x在线观看| 岛国视频午夜一区免费看| 亚洲 欧美一区二区三区| 国产亚洲欧美在线一区二区| 91在线观看av| 精品免费久久久久久久清纯| 国产精品98久久久久久宅男小说| 99riav亚洲国产免费| 免费在线观看影片大全网站| 在线观看免费午夜福利视频| 99国产极品粉嫩在线观看| 欧美丝袜亚洲另类 | 极品教师在线免费播放| 午夜日韩欧美国产| 国产精品自产拍在线观看55亚洲| 国产伦一二天堂av在线观看| 观看美女的网站| 婷婷亚洲欧美| 免费观看的影片在线观看| 国产99白浆流出| 国产欧美日韩一区二区精品| 精品电影一区二区在线| 非洲黑人性xxxx精品又粗又长| 日韩成人在线观看一区二区三区| www.精华液| 一进一出好大好爽视频| 亚洲天堂国产精品一区在线| 国产精品一区二区三区四区久久| 脱女人内裤的视频| 国产一区二区激情短视频| 亚洲无线观看免费| 色播亚洲综合网| 欧美日韩综合久久久久久 | 黄色视频,在线免费观看| 亚洲国产欧美网| 搡老妇女老女人老熟妇| 国语自产精品视频在线第100页| 麻豆av在线久日| 麻豆成人av在线观看| 欧美成人性av电影在线观看| 岛国在线观看网站| 午夜福利在线观看吧| 国产亚洲精品久久久久久毛片| 性色avwww在线观看| 亚洲成人久久性| 老司机午夜十八禁免费视频| 巨乳人妻的诱惑在线观看| 高清在线国产一区| 亚洲av成人av| 99久久99久久久精品蜜桃| 岛国在线免费视频观看| 欧美日韩综合久久久久久 | 一进一出抽搐动态| 亚洲成人精品中文字幕电影| 精品日产1卡2卡| 美女大奶头视频| av黄色大香蕉| 女生性感内裤真人,穿戴方法视频| 9191精品国产免费久久| 日本a在线网址| 熟女电影av网| 国产麻豆成人av免费视频| 成人三级黄色视频| 精品国产乱子伦一区二区三区| 夜夜爽天天搞| 亚洲乱码一区二区免费版| xxx96com| 91久久精品国产一区二区成人 | 国产精品久久久久久精品电影| 久久久久免费精品人妻一区二区| 1024手机看黄色片| 婷婷六月久久综合丁香| 亚洲专区字幕在线| 可以在线观看的亚洲视频| 国产精品久久久人人做人人爽| 欧美绝顶高潮抽搐喷水| bbb黄色大片| 亚洲精品色激情综合| h日本视频在线播放|